Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology Group

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 1038-1042

  DiSilvestro, Paul A ^a   Walker, Joan L ^b   Morrison, Astrid ^c   Rose, Peter G ^d   Homesley, Howard ^e   Warshal, David ^f  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c St Anthony Hospital Oklahoma City   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cervical carcinoma limited to the pelvis; Concomitant paclitaxel and cisplatin chemotherapy; Phase I II; Radiation therapy

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BEAM THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; ENDOCRINE DISEASE; EXTERNAL BEAM RADIOTHERAPY; EYE TOXICITY; FEMALE; FISTULA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; THYROID CRISIS; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASM STAGING; PACLITAXEL; RADIATION DOSAGE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33751423352     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.017     Document Type: Article

References (15)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. DiSaia P.J., and Creasman W.T. Invasive cervical cancer. In: DiSaia P.J., and Creasman W.T. (Eds). Clinical gynecologic oncology. 5th ed. (1997), Mosby-Year Book, St. Louis 76-89
3. Whitney C.W., Sause W.T., Bonomi P., and Liao S. A randomized comparison of hydroxyurea versus 5-FU infusion and bolus cisplatin as an adjunct to radiation therapy in patients with stages II-B, III and IV-A carcinoma of the cervix and negative para-aortic nodes. J. Clin. Oncol. 17 (1999) 1339-1348
4. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 (1999) 1137-1143
5. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 (1999) 1144-1153
6. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18 (2000) 1606-1613
7. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340 (1999) 1154-1161
8. National Cancer Institute Clinical Announcement. Concurrent chemoradiation for cervical cancer. February, 1999 (http://www.cancer.gov/newscenter/cervicalcancer).
9. McGuire W.P., Blessing J.A., Moore D., Lenta A.A., and Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 14 (1996) 792-795
10. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 3113-3119
11. Choy H., and Browne M.J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin. Oncol. S22 (1995) 70-74
12. Havemann K., Wolf M., Goerg C., Faora C., Pfab R., and Diergarten K. Paclitaxel and simultaneous radiation in the treatment of stage III A-B non-small cell lung cancer. Semin. Oncol. S22 (1995) 19-22
13. Chen M.D., Paley P.J., Potish R.A., et al. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol. Oncol. 67 (1997) 131-136
14. Fyles A., Keane T.J., Barton M., and Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother. Oncol. 28 (1992) 179-180
15. Lanciano R.M., Won M., Coia L.R., and Hanks G.E. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int. J. Radiat. Oncol. Biol. Phys. 20 (1991) 667-676